Celgene Corporation (CELG): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation ( CELG) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 2.8%. By the end of trading, Celgene Corporation fell $4.20 (-3.0%) to $136.96 on average volume. Throughout the day, 2,629,291 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,690,400 shares. The stock ranged in price between $136.60-$139.93 after having opened the day at $139.36 as compared to the previous trading day's close of $141.16. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 40.8%, Acura Pharmaceuticals ( ACUR), down 19.8%, Agios Pharmaceuticals ( AGIO), down 11.5% and Prana Biotechnology ( PRAN), down 9.4%.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $56.9 billion and is part of the health care sector. Shares are up 76.2% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Catalyst Pharmaceutical Partners ( CPRX), up 41.5%, Hi-Tech Pharmacal ( HITK), up 22.1%, GW Pharmaceuticals PLC ADR ( GWPH), up 17.5% and Akorn ( AKRX), up 9.6%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks